Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.
Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...
The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.
Eli Lilly and Company (NYSE:LLY) develops medicines for diabetes, obesity, cancer, autoimmune disorders, and neurological conditions.
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
Weight loss drugs are set to become a disproportionate share of Lilly's business.
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...
Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...
Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday. (Reporting by Kamal Choudhury in Bengaluru; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback